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Abstract
Human bocaviruses (HBoVs) 1–4 are recently discovered, antigenically similar parvovi-
ruses. We examined the hypothesis that the antigenic similarity of these viruses could give
rise to clinically and diagnostically important immunological interactions. IgG and IgM EIAs
as well as qPCR were used to study ~2000 sera collected from infancy to early adolescence
at 3–6-month intervals from 109 children whose symptoms were recorded. We found that
HBoV1-4-specific seroprevalences at age 6 years were 80%, 48%, 10%, and 0%, respec-
tively. HBoV1 infections resulted in significantly weaker IgG responses among children who
had pre-existing HBoV2 IgG, and vice versa. Furthermore, we documented a complete
absence of virus type-specific immune responses in six viremic children who had pre-exist-
ing IgG for another bocavirus, indicating that not all HBoV infections can be diagnosed sero-
logically. Our results strongly indicate that interactions between consecutive HBoV
infections affect HBoV immunity via a phenomenon called “original antigenic sin”, cross-pro-
tection, or both; however, without evident clinical consequences but with important ramifica-
tions for the serodiagnosis of HBoV infections. Serological data is likely to underestimate
human exposure to these viruses.
Introduction
Human bocavirus (HBoV) 1 is a commonly circulating human parvovirus associated with
upper respiratory tract illness (URTI). While HBoV1 acute infection often is diagnosed by
PCR analysis of respiratory samples, the interpretation of such results is complicated. The line
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between acute and past infection is blurred by a prolonged presence of the viral DNA in some
individuals, up to several months after initial infection [1–5]. Detection of HBoV1 mRNA [6,
7], serum DNA [8–11] or anti-HBoV1 antibodies [8, 11, 12] can be considered more reliable
tools for the diagnosis of primary infection.
To serodiagnose a HBoV1 infection is, however, not without caveats, due to the circulation
of three other closely related human bocaviruses, HBoV2-4 [13, 14]. In contrast to HBoV1,
these viruses occur very infrequently in respiratory specimens and appear to be enteric [15].
HBoV1-4 are structurally similar with a difference in amino acid sequence of only 10–20%
within the major structural component, viral protein 2 (VP2). This similarity manifests as sero-
logical cross-reactivity [16, 17] and may give rise to “original antigenic sin” (OAS), a long-
known phenomenon where a prior infection by a virus inhibits the immune response towards
the unique epitopes of a subsequent related virus [18], which could affect the clinical outcome.
These features have to be taken into consideration in serological assays.
Published studies assessing the clinical significance of HBoV2-4 have so far been limited to
nucleic acid-based approaches [4, 13, 19, 20]. However, the occurrence of HBoV2-4 in stool
may be prolonged similarly to many other enteric viruses [21] and to HBoV1 in the respiratory
tract [1–3, 22]. This would render PCR positivity inadequate as proof of acute primary
HBoV2-4 infection and highlight the importance of using serology (or possibly mRNA detec-
tion) in clinical assessment.
The main objectives of this study were to assess the epidemiology and immunology of
HBoV infections, and to assess their clinical significance. To this end, we used IgG and IgM
EIAs as well as qPCR to analyze sera collected from constitutionally healthy children at 3- to
6-month intervals from infancy up to adolescence. Our results reveal new aspects of HBoV epi-
demiology by showing that HBoV seroprevalences are likely to downplay the proportion of
people who have experienced infection by more than one bocavirus type. This is due to novel
interactions in humoral responses to HBoV infections, however, with no apparent clinical
consequences.
Methods
Ethical Statement
The ethics committee of the Hospital District of Southwest Finland approved the study proto-
col. The legal guardians of the study participants provided written informed consent. All clini-
cal investigation was conducted according to the principles expressed in the Declaration of
Helsinki.
Patients and Serum Samples
The participants were derived from the ongoing population-based Type 1 Diabetes Prediction
and Prevention (DIPP) study, a birth cohort study monitoring preclinical events preceding
type 1 diabetes among genetically susceptible children in Finland (for details see [23, 24]). Of
these children, 109 have previously been analyzed from infancy up to early adolescence by
HBoV1 non-competitive immunoglobulin (Ig)M, IgG, and IgG-avidity enzyme immunoassays
(EIA) and quantitative PCR (qPCR) [8, 12]. We analyzed 1,943 follow-up serum samples from
the same 109 children (median 17 samples per child, mean 18, range 12–27) followed from a
median age of 4 months (mean 3 mo, range 2–11 mo) to a median of 8 years (mean 8 y, range
4–13 y). The children were sampled at a median interval of 96 days (mean 110 d, range 55–484
d) until 2 years of age and subsequently at a median interval of 182 days (mean 197 d, range
92–849 d) until October 2008 (unless discontinued earlier). Ages shown hereafter were calcu-
lated according to the midpoints of the follow-up sampling intervals.
B-cell Responses to Human Bocaviruses
PLOS ONE | DOI:10.1371/journal.pone.0139096 September 29, 2015 2 / 12
Funds of the University of Helsinki (www.helsinki.fi/
en) to MSV, and The Sigrid Jusélius Foundation
(www.sigridjuselius.fi/foundation) to KH, MSV, and
OS. The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
At each child’s scheduled visit, the parents completed a questionnaire and were interviewed
by a study nurse on any clinical symptoms or illnesses since the previous visit. In our previous
study of this same cohort of children, the symptoms were classified by a single co-author. To
increase the accuracy of data interpretation for the present study, the symptoms were re-classi-
fied jointly by a group of three co-authors. Acute otitis media (AOM), sinusitis, tonsillitis and
lower respiratory tract infection (LRTI) were diagnosed by a physician. While diabetes-associ-
ated autoantibodies developed in 7 (6%) children, none progressed to clinical diabetes.
All serum samples were tested for HBoV1-3 IgG with and without competition with soluble
virus-like particles (VLPs), to account for serological cross-reactivity [16]. In the case of the
rare HBoV4 IgG [16, 17], only the midmost and last samples from each child were tested.
HBoV1-3 IgM and HBoV1-4 quantitative PCR (qPCR) assays were conducted on all speci-
mens showing primary or secondary IgG increases (in non-blocked EIA) and the two speci-
mens flanking these increases.
PCR was further done for 44 stool samples available from the 109 children, consecutively
obtained up to 6 months post-infection. Of these 44 stool samples, 8 were from children with
HBoV1 and 4 from children with HBoV2 infection.
Enzyme Immunoassays
Expression and purification of recombinant VLP antigens for HBoV1-4 was performed as
described [16]. IgG EIAs were conducted as described [12] except that biotinylated VLPs in the
solid phase were used at 175 ng/well, bovine serum albumin was included in the antigen dilu-
tion buffer at 25 μg/ml and the substrate incubation time was increased to 15 minutes. IgM
EIAs were carried out as described [12].
For the detection of HBoV1-specific antibodies, we competed serum samples with HBoV2
and -3 VLPs (30 μg/ml in PBS, 1.5 h, +4°C), and then tested the sera on plates with immobi-
lized HBoV1 antigen.
For preliminary detection of HBoV2 and -3 antibodies, we performed competition of the
serum samples only with HBoV1 antigen before the EIAs. Seroconversion samples, with IgG
towards both viruses, and the last follow-up sample of each child, were reanalyzed with double
competition (HBoV1+3 or HBoV1+2). The final HBoV2 and -3 seroprevalences were desig-
nated based on the double-competition assays.
Absorbances measured in these competition assays yielded the raw optical densities (OD).
Successful competition was confirmed by parallel analysis with homologous competing anti-
gen, yielding the residual ODs. The residual ODs were typically very low (median 0.03; 90th
percentile, 0.11). To avoid false positive results due to incomplete antibody competition, the
net OD was calculated by subtracting the residual OD from the raw OD. Competed samples
were designated antibody positive or negative based on the net OD.
To determine the HBoV1 IgM-EIA cutoff, we selected serum samples from children aged
>8 years on the basis that HBoV1 primary infections are highly uncommon in this age group
[8]. Samples with major (>0.5 OD) fluctuations in IgG levels in the neighboring follow-up
samples were excluded, yielding 138 samples from 27 children. The cutoffs (mean + 4 SDs)
were 0.131 and 0.092 for the respective non-competed and competed IgM assays.
For IgG-EIA cutoff determination we selected samples (n = 111) preceding HBoV1 IgM
seroconversion or HBoV1 viremia. Cutoff absorbances (mean + 4 SDs) for positive competed
and non-competed IgG EIA results were 0.151 and 0.095, respectively. The HBoV1 IgG- and
IgM-EIA cutoffs were applied to HBoV2-4 EIAs as such based on the uniformity of the protein
purification and EIA methods and due to inadequate number of HBoV2-4 control sera.
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Unless explicitly stated, all references to the occurrence of IgG or IgM in the following text
and Tables 1–3 are based on the virus-specific competition assays, or such non-competition
assays where only a single virus showed a positive IgG or IgM result.
Results
IgG Seroprevalence
HBoV1-3 seroprevalences as a function of age are illustrated in Fig 1. Individual ELISA results
of all 109 children are illustrated graphically in S1 Supporting Information. All children sero-
converted for at least one HBoV by the age of 4.8 y. The median age of seroconversion for
those who seroconverted within the follow-up, was 1.9 years (range 0.5–8.0) for HBoV1, 1.6
years (range 0.4–9.3) for HBoV2 and 1.7 years (range 0.4–5.8) for HBoV3. By the age of 6
years, among those 93 (85%) children who still remained in follow-up, the seroprevalences for
HBoV1, 2 and 3 were 80%, 48% and 10%, respectively. No HBoV4 IgG was detected in any of
the children.
HBoV1-3 IgG reversions were evident in 10/94 (11%), 13/58 (22%) and 3/11 (27%) seropos-
itive children, respectively. These IgG reversions were due to weak IgG responses that waned
below cutoff over time (e.g. child #13 in S1 Supporting Information). Of the IgG-reverted chil-
dren, one-third later regained HBoV1 IgG and two-thirds HBoV2 IgG.
Table 1. HBoV1-3 IgG stability among 109 constitutionally healthy children.
HBoV1 HBoV2 HBoV3
IgG+ 94 58 11
High & stable IgGa 43 (46%) 0 0
Substantial IgG decreaseb 8 (9%) 21 (36%) 4 (36%)
Secondary IgG increasec 2 (2%) 22 (38%) 5 (45%)
Remaining children 41 (44%) 15 (26%) 2 (18%)
Abbreviations: HBoV1, human bocavirus 1; HBoV2, human bocavirus 2; HBoV3, human bocavirus 3; IgG,
immunoglobulin G
a Competed IgG showed no signiﬁcant waning and remained above 2.0 absorbance units from initial
seroconversion to the end of the follow-up period
b 2 absorbance unit decrease in optical density after seroconversion
c 2 absorbance unit increase in optical density in two consecutive samples, both obtained at least 4
months after IgG seroconversion
Note: the percentages do not necessarily add up to 100% because of rounding up.
doi:10.1371/journal.pone.0139096.t001
Table 2. Co-occurrence of IgM or viremia with human bocavirus 1, 2 or 3 primary IgG seroconversions among 109 constitutionally healthy
children.
IgG
seroconversion
Viremia IgM IgG seroconversion with
viremia
IgG seroconversion with
IgM
IgG seroconversion with viremia
and IgM
HBoV1 94 24 35 22 32 10
HBoV2 58 8 11 4 10 2
HBoV3 11 1 0 1 0 0
Note: data are no. of patients. Viremia or IgM was regarded to coincide with IgG seroconversion if they were present in the ﬁrst IgG positive sample or the
sample preceding this sample. HBoV4 is excluded from the table due to absence of detectable infections. Abbreviations: HBoV, human bocavirus; IgG,
immunoglobulin G; IgM, immunoglobulin M.
doi:10.1371/journal.pone.0139096.t002
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IgG Stability
There was significant variability in HBoV1-3 IgG OD stability between individual children.
Typically, however, HBoV1 IgG levels remained higher and more stable than those of HBoV2
(Tables 1). The latter were characterized by repeated sharp increases and decreases (e.g. subject
#52 in Fig 2). Based on the limited data, HBoV3 IgG profiles resembled those of HBoV2.
Table 3. Infection-related symptoms during human bocavirus 1 and 2 primary seroconversions compared with those of the previous and subse-
quent sampling intervals.
Primary HBoV1 immune responses, n = 64 Primary HBoV2 immune responses, n = 44
SC interval previous interval next interval SC interval previous interval next interval
Symptom no. (%) no. (%) p value no. (%) p value no (%) no. (%) p value no. (%) p value
URTI 29 (45) 31 (48) 0.86 20 (31) 0.12 13 (30) 14 (32) 1.0 17 (39) 0.50
Gastroenteritis 14 (22) 11 (17) 0.66 10 (16) 0.50 14 (32) 6 (14) 0.08 8 (18) 0.24
Acute otitis media 31 (48) 20 (31) 0.04* 23 (36) 0.20 12 (27) 6 (14) 0.18 12 (27) 1.0
Note: ﬁrst HBoV1 seroconversion was regarded as primary regardless of the presence or absence of pre-existing HBoV2 or -3 IgG, and vice versa. SC,
seroconversion; URTI, upper respiratory tract illness; HBoV1, human bocavirus 1; HBoV2, human bocavirus 2.
Boldface and * indicate statistical signiﬁcance by Liddell exact test (<0.05).
doi:10.1371/journal.pone.0139096.t003
Fig 1. Human bocavirus 1–3 seroprevalences (dashed lines) and cumulative seroconversion rates (solid lines) in different age groups.
doi:10.1371/journal.pone.0139096.g001
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IgG Co-Occurrence
HBoV2 IgG occurred more rarely in patients with HBoV1 IgG than without, and vice versa.
All 15 subjects without, but only 43 of 94 (46%) subjects with HBoV1 IgG showed also HBoV2
or -3 IgG. Similarly, all 51 subjects without, but only 43 of 58 (74%) with HBoV2 or -3 IgG,
showed also HBoV1 IgG. Both results were statistically highly significant (p<0.001) by Fisher's
exact test. HBoV3-positive subjects were too few for meaningful statistical analysis.
The presence of HBoV2 or -3 IgG antibodies preceding HBoV1 IgG was also inversely asso-
ciated with HBoV1 IgG levels. Only 8 of 22 (36%) children with HBoV2 or -3 IgG preceding
HBoV1 seroconversion, developed moderate or high HBoV1 IgG absorbances (> 1.0) in con-
trast to all 68 non-primed children (p<0.0001 by Fisher’s exact test). Subjects #53 and #122 in
Fig 3 demonstrate HBoV1 responses in children without or with pre-existing HBoV2 IgG,
respectively. Likewise, the presence of HBoV1 IgG prior to HBoV2 seroconversion was associ-
ated with low IgG reactivity toward the latter. Of 17 children with pre-existing HBoV1 IgG,
only 7 (41%) developed moderate to high HBoV2 IgG absorbances as opposed to all 37 (100%)
non-primed children. Subjects #52 and #108 in Fig 2 demonstrate HBoV2 responses in chil-
dren without or with pre-existing HBoV1 IgG, respectively.
Waning maternal IgG against HBoV1 was detected in 51%, and against HBoV2 or HBoV3
in 7%, of 88 children from whom the first sample was taken within the first 6 months after
birth. As with primary infections, the maternal HBoV1 IgG levels were more pronounced than
those of HBoV2.
Fig 2. Pre-existing HBoV1 IgG reduces immune response against HBoV2 infection. Two representative cases of PCR-verified HBoV2 infections
without (child #52) or with (child #108) pre-existing HBoV1 IgG are shown. The red, blue and black data points respectively indicate whether the serum tested
positive by PCR, tested negative by PCR, or was not tested by PCR. Although not shown in the graphs, both children tested negative for HBoV3- and
4-specific IgG.
doi:10.1371/journal.pone.0139096.g002
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IgM
IgM for HBoV1 or -2 was detected almost exclusively in conjunction with a seroconversion for
the corresponding (competed) IgG (Tabel 2). Only 3 subjects showed HBoV1 IgM in more
than one follow-up sample, potentially due to nonspecific reactivity. All HBoV2 IgM reactivi-
ties lasted<6 months after seroconversion. No HBoV3 IgM was observed.
Detection of HBoV1 IgM was very rare in children who already were seropositive for
HBoV2 or -3. It occurred in 32 of 61 (52%) children in whom HBoV1 was the first infecting
HBoV but only in 2 of 48 (4%) children primed with HBoV2 or -3.
Reassessment of HBoV1 Serology
We have previously studied this same cohort with HBoV1 EIA assays without competition [8]
and found that all the 109 children became IgG seropositive by 6 years of age. The present
HBoV1 IgG results are, based on the new competition EIA, notably different; 15 of the 109
children showed no detectable HBoV1 IgG at any time point but instead showed HBoV2 or -3
IgG. Further 12 children experienced seroconversion of HBoV1-specific IgG at a later time
point than determined by the non-competition assay (exemplified by subject #52 in Fig 2). On
the other hand, the effect of HBoV2 and HBoV3 circulation on our HBoV1 IgM results appears
to have been minimal, with only one of the 39 previously observed HBoV1 IgM positives [8]
being apparently due to the enteric bocaviruses.
Fig 3. Pre-existing HBoV2 IgG reduces immune response against HBoV1 infection. Two illustrative cases of PCR-verified HBoV1 infections without
(child #53) or with (child #122) pre-existing HBoV2 IgG are shown. The red, blue and black data points respectively indicate whether the serum tested
positive by PCR, tested negative by PCR, or was not tested by PCR. The red open circle indicates a sample that was positive for HBoV1 IgM. Although not
shown in the graphs, both children tested negative for HBoV3- and 4-specific IgG.
doi:10.1371/journal.pone.0139096.g003
B-cell Responses to Human Bocaviruses
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Real-Time qPCR
The occurrence of HBoV1 viremias in this cohort of 109 children has been determined previ-
ously [8]. Of the 94 HBoV1-infected children, 24 (26%) were viremic around the time of infec-
tion, however, none of the 27 children with a previous false HBoV1 seroconversion had
viremia at that time. HBoV2 or -3 viremia was detected respectively in four of 58 (7%) and one
of 11 (9%) children with corresponding IgG conversion. Of note, none of the children showed
repeated viremia by any given bocavirus type.
Almost all HBoV1 viremias were observed concurrently with a seroconversion for (com-
peted) HBoV1 IgG (Table 2). HBoV2 or HBoV3 IgG preceded the HBoV1 viremia in five of
the 24 viremic cases. Two of these five HBoV1 viremias were not associated with observable
production of HBoV1 IgG in competition EIA, even though significant increases in HBoV1
IgG were seen in the non-competition EIA (e.g. child #122 in Fig 3).
In contrast to HBoV1, only 4 of the 8 HBoV2 viremias were associated with a concurrent
primary IgG seroconversion for the virus. None of these 4 seroconverting children showed pre-
existing antibodies for any bocavirus. The remaining 4 children were primed with HBoV1
(n = 3) or HBoV3 (n = 1) IgG before the appearance of HBoV2 viremia and showed no HBoV2
IgG responses; one such case is illustrated in Fig 2 (subject #108). To confirm these results, the
serum DNA of each child was re-isolated from a separate aliquot. All 8 detections of HBoV2
viremia were found to be reproducible.
For HBoV1, the DNA loads in the 5 viremic children primed with HBoV2 or -3 IgG were
1.3×100–2.2×104 copies/ml, whereas those for the 19 non-primed viremic children were
5.3×103 to 9.1×105 copies/ml. Furthermore, all HBoV2 (n = 8) and HBoV3 (n = 1) viral loads
(<7×103 copies/ml) were even lower, near the limits of reliable qPCR detection. The numbers
of children and the virus loads were too low for meaningful statistical analysis of the possible
influence of prior immunity on secondary heterologous virus replication.
No child tested DNA positive for multiple bocavirus species in any given sample. Alto-
gether, only one child (#5 in S1 Supporting Information) tested viremic more than once; for
HBoV3 DNA at the age of 3 months and for HBoV2 at 4.1 years. The child had also HBoV1
IgG, thus representing the only case of a reasonably verified triple HBoV infection in the
cohort, serologically visible only in the non-competition EIA as three successive IgG peaks.
Half of the 8 HBoV1-infected children with consecutive stools showed HBoV1 DNA in the
first stool 0.5–1.1 months after seroconversion but not later. In contrast, all 4 HBoV2-infected
children with consecutive stools had HBoV2 DNA in the first stool, and 3 had in several stools,
lasting 1,2 or 5 months after seroconversion.
Clinical Correlates
By comparing signs and symptoms during the seroconversion (SC) interval with those during
the flanking intervals of each child, a statistically significant association (p<0.05 by Liddell
exact test) was observed between HBoV1 and AOM (p = 0.04, for one of the two flanking inter-
vals) but not for the other two common illnesses URTI and gastroenteritis (Table 3). Other
symptoms (LRTI, fever, tonsillitis, conjunctivitis, sinusitis & exanthema) were observed too
rarely for meaningful statistical analyses (data not shown). The severity of symptoms reported
during secondary HBoV1-infection intervals, and their flanking intervals, did not markedly
differ in the 15 children lacking specific secondary IgG responses, compared with the children
exhibiting a robust secondary immune response. The HBoV2-infected children showed more
gastrointestinal symptoms during the infection interval than in the flanking intervals, without
reaching statistical significance (Table 3). The low number of children prevented symptom
analysis of HBoV3 and -4 infections.
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Discussion
We have previously provided evidence to indicate that most HBoV1 infections are serologically
specific even without antigen competition in the acute infection phase [16]. However, two
aspects of this notion should be clarified. First, specificity depends heavily on the experimental
methodology. Our current non-competition EIAs with elevated antigen loads do show cross-
reactivity in some acute-phase patients with high antibody levels. Second, HBoV1 IgG serocon-
version in a non-competition assay by itself is not a definite marker of an acute HBoV1 infec-
tion because the seroconversion can be due to a rise in HBoV2-4 IgG.
In our earlier assessment of the etiological role of HBoV1 in these same 109 constitutionally
healthy children [8], we nevertheless used non-competition-IgG seroconversion as the prime
marker of acute infection. We found that acute HBoV1 infection was strongly associated with
upper respiratory tract infection and less with acute otitis media. However, the present reas-
sessment of HBoV1 clinical correlates, with revised methodology, surprisingly showed only a
weak correlation with acute otitis media and none with respiratory illness. Reasons for the dis-
crepancy might be that the new procedure yielded a different set of HBoV1-positive subjects
resulting in 64 vs. 101 children, and that the URTI symptoms in 38 children were classified dif-
ferently upon blinded re-evaluation by a group of three co-authors. Despite the uniquely high
serum sampling coverage, the intervals were possibly still too long for significance assessment
among children of this age, with several URTIs a year.
We have previously hypothesized that, in contrast to the systemic HBoV1 infections, infec-
tions by the enteric bocaviruses would be local and result in weak immune reactions [16]. This
notion was based on the less frequent detection of HBoV2 or HBoV3 IgG among adults than
children, on the low level of IgG in seropositive adults, and on the lack of viremia in children.
Our present data show that in some children primary HBoV2 and HBoV3 infections can pres-
ent with markers of systemic infection, i.e. viremia and a strong IgG response. Nevertheless, on
the whole HBoV2 and possibly HBoV3 viremias appear to be rare, low-titered, and/or short-
lived, and the corresponding IgG responses are generally weaker and more prone to waning
than those of HBoV1. While boosts of these initially low HBoV2 and -3 IgG levels appear com-
monly, they do not seem to prevent the IgG from waning. Even if our pediatric follow-up
period did not extend beyond the early teens, the very low incidence of maternal HBoV2 or -3
IgG in the infants supports our previous observation of low (or undetectable) IgG levels in
adults [16].
We observed several PCR-verified heterologous secondary infections that failed to stimulate
significant production of IgG specific for the boosting virus. Instead, the immunostimulatory
effect, visualized by non-competition EIAs, preferentially targeted epitopes shared with the
priming virus. We also noted that when the secondary (type-specific) IgG responses did
emerge, they were typically weak in comparison to the corresponding primary IgG responses.
Furthermore, HBoV1 IgM responses were almost completely absent from individuals with
prior HBoV2 or -3 IgG, as compared to half of those with HBoV1 as the first HBoV infection.
These results are in line with the proposed phenomenon of original antigenic sin (OAS), i.e.
the propensity of the body’s immune system to become primed by an antigen and subsequently
disregard, partially or completely, the novel epitopes of related subsequent antigens [18, 25,
26].
The OAS concept was originally formulated by influenza virus researchers in the 1960s and
has since been associated with several other viruses, including dengue viruses (DENV) as a fre-
quently cited example [27–29]. In DENV infections, severe symptoms such as high fever and
shock from increased vascular permeability appear to occur more often in secondary than in
primary infections [30, 31]. The aggravated DENV infections may involve OAS preventing the
B-cell Responses to Human Bocaviruses
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formation of neutralizing antibodies against novel epitopes. The subsequent circulation of
poorly neutralizing cross-reactive antibodies may assist infection by otherwise noninfectious
immature DENV particles via Fcγ receptor-bearing hosts such as macrophages in a phenome-
non known as antibody-dependent enhancement of infection (ADE). The latter has been
observed not only with DENV [32, 33] and influenza viruses [34, 35] but also with parvoviruses
such as Aleutian mink disease parvovirus and human parvovirus B19 [36–39].
OAS is generally perceived as a detrimental phenomenon that may clinically aggravate infec-
tions or expose a host to repeated infections. In our clinical evaluation, however, no such effects
were evident. Unfortunately, the occurrence of PCR-verified OAS was too infrequent for statisti-
cally relevant analysis. On the other hand, despite the existence of such viremias, our data could
perhaps be explained by cross-protection, whereby pre-existing immunity against one bocavirus
limits the propagation of another. This could prevent the secondary antigen from reaching the
quantity threshold required for efficient naïve B-cell activation. In other words, the absence or
weakness of the secondary responses could reflect the virtue of an efficiently functioning primary
immune memory rather than the sin of an imperfect secondary response. Indeed, we are not sure
to what extent existing OAS literature could be explained by immunological cross-protection
rather than a "blind spot" in the immune system. However, we have recently studied immune
responses in rabbits sequentially immunized with recombinant HBoV1-4 VLPs and observed
muted antibody responses against the secondary antigens in several animals [40]. Considering
that the animals were exposed to hundreds of micrograms of antigen (as opposed to minute
doses of live viruses), it seems unlikely that the diminished secondary antibody responses could
be explained solely by antigen elimination by a cross-reactive immune system.
Regardless of the clinical significance or the exact mechanism of weak B-cell responses to sec-
ondary (heterologous) HBoV1-4 infections, our results have important diagnostic ramifications
for the serodiagnostic assessment of HBoV infections. We documented six cases of HBoV vire-
mia that did not result in an observable species-specific antibody response against the viremic
species. Such data indicate that most but not all HBoV infections can be diagnosed serologically.
More such viremic cases in our study may have gone unrecognized due to the long sampling
intervals (3–6 months) and selective PCR testing of the sera. This indicates that the seropreva-
lences obtained here and elsewhere for HBoV1-4 are, due to both IgG waning and OAS,
undoubtedly underestimations of the extent to which people are exposed to these viruses. For
comparison, a relatively recent DENV study illustrated the persisting difficulty of serologically
diagnosing secondary DENV infections, despite these viruses having been known for decades. By
using serum PCR as "gold standard", the authors were able to infer the correct secondary DENV
serotype with 67% accuracy based on pre- and postinfection neutralizing antibody titers [41].
Highly accurate serologic differentiation of secondary HBoV infections may prove to be an
equally elusive task. Serodiagnosis of HBoV infections nevertheless remains as important as ever
since the clinical significance of secondary HBoV infections is yet to be fully assessed.
Supporting Information
S1 Supporting Information. ELISA results of all 109 children in graphical format.
(PDF)
Author Contributions
Conceived and designed the experiments: KK KHMSV. Performed the experiments: KK LH JP
MS. Analyzed the data: KK LT MSV. Contributed reagents/materials/analysis tools: VS MM
RVMK JI HH JT OS. Wrote the paper: KK JP MSV.
B-cell Responses to Human Bocaviruses
PLOS ONE | DOI:10.1371/journal.pone.0139096 September 29, 2015 10 / 12
References
1. Blessing K, Neske F, Herre U, Kreth HW,Weissbrich B. Prolonged detection of human bocavirus DNA
in nasopharyngeal aspirates of children with respiratory tract disease. Pediatr Infect Dis J. 2009; 28:
1018–1019. doi: 10.1097/INF.0b013e3181a854ae PMID: 19730155
2. Martin ET, Fairchok MP, Kuypers J, Magaret A, Zerr DM, Wald A et al. Frequent and prolonged shed-
ding of bocavirus in young children attending daycare. J Infect Dis. 2010; 201: 1625–1632. doi: 10.
1086/652405 PMID: 20415535
3. Lehtoranta L, Söderlund-Venermo M, Nokso-Koivisto J, Toivola H, Blomgren K, Hatakka K et al.
Human bocavirus in the nasopharynx of otitis-prone children. Int J Pediatr Otorhi. 2012; 76: 206–211.
4. Paloniemi M, Lappalainen S, Salminen M, Kätkä M, Kantola K, Hedman L et al. Human bocaviruses
are commonly found in stools of hospitalized children without causal association to acute gastroenteri-
tis. Eur J Pediatr. 2014; 173: 1051–1057. doi: 10.1007/s00431-014-2290-x PMID: 24590657
5. Martin ET, Kuypers J, McRoberts JP, Englund JA, Zerr DM. Human Bocavirus 1 Primary Infection and
Shedding in Infants. J Infect Dis. 2015; Advance Access, published March 2, 2015.
6. Proença-Modena JL, Gagliardi TB, Paula FE, Iwamoto MA, Criado MF, Camara AA et al. Detection of
human bocavirus mRNA in respiratory secretions correlates with high viral load and concurrent diar-
rhea. PLoS One. 2011; 6: e21083. doi: 10.1371/journal.pone.0021083 PMID: 21701591
7. Christensen A, Døllner H, Skanke LH, Krokstad S, Moe N, Nordbø SA. Detection of spliced mRNA from
human bocavirus 1 in clinical samples from children with respiratory tract infections. Emerg Infect Dis.
2013; 19: 574–580. doi: 10.3201/eid1904.121775 PMID: 23628409
8. Meriluoto M, Hedman L, Tanner L, Simell V, Mäkinen M, Simell S et al. Association of human bocavirus
1 infection with respiratory disease in childhood follow-up study, Finland. Emerg Infect Dis. 2012; 18:
264–271. doi: 10.3201/eid1802.111293 PMID: 22305021
9. Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R et al. Human bocavirus and acute
wheezing in children. Clin Infect Dis. 2007; 44: 904–910. PMID: 17342639
10. Christensen A, Nordbø SA, Krokstad S, Rognlien AG, Døllner H. Human bocavirus in children: mono-
detection, high viral load and viraemia are associated with respiratory tract infection. J Clin Virol. 2010;
49: 158–162. doi: 10.1016/j.jcv.2010.07.016 PMID: 20833582
11. Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O et al. Serodiagnosis of human
bocavirus infection. Clin Infect Dis. 2008; 46: 540–546. doi: 10.1086/526532 PMID: 18199037
12. Söderlund-VenermoM, Lahtinen A, Jartti T, Hedman L, Kemppainen K, Lehtinen P et al. Clinical
assessment and improved diagnosis of bocavirus-induced wheezing in children, Finland. Emerg Infect
Dis. 2009; 15: 1423–1430. doi: 10.3201/eid1509.090204 PMID: 19788810
13. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM. A novel bocavirus associated with acute
gastroenteritis in Australian children. PLoS Pathog. 2009; 5: e1000391. doi: 10.1371/journal.ppat.
1000391 PMID: 19381259
14. Kapoor A, Simmonds P, Slikas E, Li L, Bodhidatta L, Sethabutr O et al. Human bocaviruses are highly
diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis. 2010; 201:
1633–1643. doi: 10.1086/652416 PMID: 20415538
15. Chieochansin T, Kapoor A, Delwart E, Poovorawan Y, Simmonds P. Absence of detectable replication
of human bocavirus species 2 in respiratory tract. Emerg Infect Dis. 2009; 15: 1503–1505. doi: 10.
3201/eid1509.090394 PMID: 19788826
16. Kantola K, Hedman L, Arthur J, Alibeto A, Delwart E, Jartti T et al. Seroepidemiology of human boca-
viruses 1–4. J Infect Dis. 2011; 204: 1403–1412. doi: 10.1093/infdis/jir525 PMID: 21921203
17. Guo L, Wang Y, Zhou H, Wu C, Song J, Li J et al. Differential seroprevalence of human bocavirus spe-
cies 1–4 in Beijing, China. PLoS One. 2012; 7: e39644. doi: 10.1371/journal.pone.0039644 PMID:
22761854
18. Francis T Jr. On the doctrine of original antigenic sin. P Am Philos Soc. 1960; 104: 572–578.
19. Jin Y, ChengWX, Xu ZQ, Liu N, Yu JM, Li HY et al. High prevalence of human bocavirus 2 and its role
in childhood acute gastroenteritis in China. J Clin Virol. 2011; 52: 251–253. doi: 10.1016/j.jcv.2011.07.
012 PMID: 21907613
20. Nawaz S, Allen DJ, Aladin F, Gallimore C, Iturriza-Gómara M. Human bocaviruses are not significantly
associated with gastroenteritis: results of retesting archive DNA from a case control study in the UK.
PLoS One. 2012; 7: e41346. doi: 10.1371/journal.pone.0041346 PMID: 22848470
21. Kapusinszky B, Minor P, Delwart E. Nearly constant shedding of diverse enteric viruses by two healthy
infants. J Clin Microbiol. 2012; 50: 3427–3434. doi: 10.1128/JCM.01589-12 PMID: 22875894
B-cell Responses to Human Bocaviruses
PLOS ONE | DOI:10.1371/journal.pone.0139096 September 29, 2015 11 / 12
22. von LinstowML, Høgh M, Høgh B. Clinical and epidemiologic characteristics of human bocavirus in
Danish infants: results from a prospective birth cohort study. Pediatr Infect Dis J. 2008; 27: 897–902.
doi: 10.1097/INF.0b013e3181757b16 PMID: 18756188
23. Nejentsev S, Sjöroos M, Soukka T, Knip M, Simell O, Lövgren T et al. Population-based genetic screen-
ing for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the
HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med. 1999; 16: 985–992. PMID: 10656226
24. Ilonen J, Sjöroos M, Knip M, Veijola R, Simell O, Åkerblom HK et al. Estimation of genetic risk for type 1
diabetes. Am J Med Genet. 2002; 115: 30–36. PMID: 12116174
25. Davenport FM, Hennessy AV. A serologic recapitulation of past experiences with influenza A; antibody
response to monovalent vaccine. J Exp Med. 1956; 104: 85–97. PMID: 13332182
26. Jensen KE, Davenport FM, Hennessy AV, Francis TJ. Characterization of influenza antibodies by
serum absorption. J Exp Med. 1956; 104: 199–209. PMID: 13345965
27. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A
et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med.
2003; 9: 921–927. PMID: 12808447
28. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A et al. An in-depth
analysis of original antigenic sin in dengue virus infection. J Virol. 2011; 85: 410–421. doi: 10.1128/JVI.
01826-10 PMID: 20980526
29. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat
Rev Immunol. 2011; 11: 532–543. doi: 10.1038/nri3014 PMID: 21760609
30. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V et al. Risk factors
in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 out-
break. Am J Epidemiol. 1984; 120: 653–669. PMID: 6496446
31. GuzmanMG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S et al. Epidemiologic studies on Dengue
in Santiago de Cuba, 1997. Am J Epidemiol. 2000; 152: 793–9; discussion 804. PMID: 11085389
32. Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature.
1977; 265: 739–741. PMID: 404559
33. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively trans-
ferred antibody. J Infect Dis. 1979; 140: 527–533. PMID: 117061
34. Tamura M, Webster RG, Ennis FA. Antibodies to HA and NA augment uptake of influenza A viruses
into cells via Fc receptor entry. Virology. 1991; 182: 211–219. PMID: 2024464
35. Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to
influenza A viruses. J Virol. 1994; 68: 3499–3504. PMID: 8189489
36. Kanno H, Wolfinbarger JB, BloomME. Aleutian mink disease parvovirus infection of mink macrophages
and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infec-
tion. J Virol. 1993; 67: 7017–7024. PMID: 8230426
37. BloomME, Best SM, Hayes SF, Wells RD, Wolfinbarger JB, McKenna R et al. Identification of aleutian
mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection,
virus neutralization, and immune complex formation. J Virol. 2001; 75: 11116–11127. PMID: 11602751
38. Munakata Y, Kato I, Saito T, Kodera T, Ishii KK, Sasaki T. Human parvovirus B19 infection of monocytic
cell line U937 and antibody-dependent enhancement. Virology. 2006; 345: 251–257. PMID: 16246390
39. von Kietzell K, Pozzuto T, Heilbronn R, Grössl T, Fechner H, Weger S. Antibody-mediated enhance-
ment of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.
J Virol. 2014; 88: 8102–8115. doi: 10.1128/JVI.00649-14 PMID: 24807719
40. Li X, Kantola K, Hedman L, Arku B, Hedman K, Söderlund-VenermoM. Original antigenic sin with
human bocaviruses 1–4. J Gen Virol. Advance online publication. doi: 10.1099/jgv.0.000253 PMID:
26224569
41. van PanhuisWG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A et al. Inferring the
serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing anti-
body titers. J Infect Dis. 2010; 202: 1002–1010. doi: 10.1086/656141 PMID: 20738205
B-cell Responses to Human Bocaviruses
PLOS ONE | DOI:10.1371/journal.pone.0139096 September 29, 2015 12 / 12
